



FOR IMMEDIATE RELEASE

May 9, 2023

Listed Company Name: Eisai Co., Ltd.
 Representative: Haruo Naito
 Representative Corporate Officer and CEO
 Securities Code: 4523
 Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
 Inquiries: Sayoko Sasaki
 Vice President,
 Corporate Communications
 Phone +81-3-3817-5120

Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2023

Eisai Co., Ltd. (“the Company”) announced today that based on trends in business results, etc., the Company has revised its consolidated financial forecasts for the fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023) previously announced on November 7, 2022, as follows.

1. Revised consolidated financial forecasts for the fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the year	Profit attributable to owners of the parent	Basic earnings per share
Previously announced forecast (A) (November 7, 2022)	760,000	55,000	56,500	58,000	57,000	197.80 yen
Currently revised forecast (B)	744,000	40,000	45,000	56,500	55,000	193.30 yen
Change in amount (B - A)	(16,000)	(15,000)	(11,500)	(1,500)	(2,000)	
Percentage of change (%)	(2.1%)	(27.3%)	(20.4%)	(2.6%)	(3.5%)	
(Reference) Business results for the fiscal year ended March 31, 2022	756,226	53,750	54,458	45,717	47,954	167.27 yen

2. Reason for revision of the consolidated financial forecasts

Based on trends in foreign exchange and product sales, revenue is expected to be ¥744.0 billion, a decrease of ¥16.0 billion from the previous forecast (of which approximately ¥9.5 billion is due to foreign exchange fluctuations).

Due to the decrease in gross profit resulting from the decline in revenue (a decrease of approximately ¥9.5 billion from the previous forecast) and the increase in R&D expenses (an increase of ¥6.5 billion from the previous forecast) resulting from aggressive investments with the good progress of clinical trials for Alzheimer's disease treatment lecanemab and the review of existing development projects, operating profit is expected to be ¥40.0 billion, a decrease of ¥15.0 billion from the previous forecast.

As a result of the decrease in operating profit and other factors, tax expenses are expected to decrease ¥10.0 billion from the previous forecast, profit for the year is expected to be ¥56.5 billion, a decrease of ¥1.5 billion from the previous forecast, and profit attributable to owners of the parent is expected to be ¥55.0 billion, a decrease of ¥2.0 billion from the previous forecast.

The annual dividend forecast remains unchanged at ¥160 per share, with the year-end dividend of ¥80 per share (same amount as the previous period) together with the interim dividend (end of the second quarter) of ¥80 per share, as previously forecast.

* Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of May 9, 2023.
